Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

The present invention relates to antifungal and antibacterial activity of processed Morinda citrifolia products, as well as from various fractions of extracts from these processed products and the Morinda citrifolia L. plant, and related methods to determine mean inhibitory concentrations. In particular, the present invention relates to ethanol, methanol and ethyl acetate extracts from Morinda citrifolia L. and their inhibitory activities on common fungi and bacteria and the identification of mean inhibitory concentrations.

InventorsScott Gerson, Afa Kehaati Palu, Bing-Nan Zhou, Chen Su, Claude Jarakae Jensen, Stephen P. Story, Robert V. Ogden
Original AssigneeMorinda, Inc.
Primary Examiner: Patricia Leith
Attorneys: Kirton & McConkie, Michael F. Krieger
Current U.S. Classification424/725

View patent at USPTO
Search USPTO Assignment Database
Download USPTO Public PAIR data

Referenced by

Citing PatentFiling dateIssue dateOriginal AssigneeTitle
US7442395Jan 26, 2006Oct 28, 2008Tahitian Noni International, Inc.Formulation for treating candidiasis using Morinda citrifolia
US7955826Jun 15, 2007Jun 7, 2011Polymer Ventures, Inc.Composition and methods for improving the production of fermentation operations
US8025910May 10, 2007Sep 27, 2011Tahitian Noni International, Inc.Method and composition for administering bioactive compounds derived from Morinda citrifolia

Claims

1. A formulation for inhibiting fungal and microbial growth within a mammal, said formulation comprising:

Quercetin between about 0.01 and 50 percent by weight;

Morinda citrifolia oil between about 0.1 and 30 percent by weight; and

processed Morinda citrifolia puree juice between about 0.01 and 99.9 percent by weight.

2. The formulation of claim 1, wherein said processed formulation further comprises Rutin as an additional active ingredient.

3. The formulation of claim 2, wherein said Rutin is present in an amount between about 0.1 and 10 percent by weight.

4. The formulation of claim 1, wherein said formulation is administered via a method selected from the group consisting of orally, transdermally, by injection into said infected area, intravenously, and systemically.